Moderna Raises Full-Year Growth Outlook to 15% to 25% After Q3 Earnings Beat

Moderna raised its full-year growth outlook to 15% to 25% after third-quarter results showed revenue growth and an earnings beat. Higher overseas sales of its COVID-19 vaccines drove the revenue growth and helped produce the earnings beat. John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TokenPost.